Executive Vice President and Chief Research and Academic Officer
Alfred Lerner Memorial Chair in Innovative Biomedical Research
Cleveland Clinic
Serpil Erzurum, MD, is Executive Vice President, Cleveland Clinic’s Chief Research and Academic Officer and Chief of Research. She holds the Alfred Lerner Memorial Chair in Innovative Biomedical Research.
Dr. Erzurum focuses on strategic growth of enterprise-wide medical and scientific education programs; clinical, basic and translational research; and technology development to deliver the most innovative care to patients.
A practicing pulmonologist and active scientist, her scientific contributions and leadership in pulmonary research have led to diagnostic and therapeutic advances in lung diseases and have helped to identify human physiologic adaptive responses to high-altitude hypoxia. She has published more than 350 peer-reviewed articles, is among the top 1% cited researchers in the world and has been the principal investigator on more than 20 federal grants, including multi-investigator program project grants and network trials. She also is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Erzurum has earned numerous awards, including the MERIT award from the National Heart, Lung and Blood Institute. She is an elected member of the National Academy of Medicine, American Society for Clinical Investigation, and Association of American Physicians, where she served as president from 2017-2018. She also has served as chair of the Pulmonary Disease Board of the American Board of Internal Medicine. Dr. Erzurum has been honored several times by the American Thoracic Society, receiving the Elizabeth Rich Award for her contributions to mentorship and in advancing the careers of women in medicine and science, and most recently, the Robert F. Grover Award for outstanding contributions to the study of the effects of hypoxia and high altitude on pulmonary circulation.
Dr. Erzurum earned her medical degree from Northeastern Ohio Universities College of Medicine and completed residency training in internal medicine at Baylor College of Medicine. She completed fellowship training at the University of Colorado Health Sciences Center and postdoctoral training at the National Heart, Lung and Blood Institute in Bethesda, Maryland.
Chief Research Information Officer
The Sondra J. And Stephen R. Hardis Endowed Chair for Research and Technology
Neurologist
Cleveland Clinic
Lara Jehi, MD, MHCDS, is Cleveland Clinic’s inaugural Chief Research Information Officer and holder of the Sondra J. and Stephen R. Hardis Endowed Chair for Research and Technology. She is professor of neurology at Cleveland Clinic Lerner College of Medicine, and an epilepsy specialist.
Dr. Jehi is Executive Program lead for the Discovery Accelerator, which now spans more than 60 projects focused on artificial intelligence, quantum computing, data science education and numerous international initiatives, including with the U.K.’s Science and Technology Facilities Council’s (STFC) Hartree Centre and the Novo Nordisk Foundation in Denmark. She led the creation of the Ohio Quantum Institute with Miami University, building the quantum talent pipeline through bachelor’s, master’s, and PhD degrees in quantum computing, and co-leads the Advanced Computational Life Sciences Center of Excellence between Cleveland Clinic and Carnegie Mellon University focused on collaborative research in drug and biomarker discovery, Neuroquantum technologies, and quantum-centric-supercomputing. She supports research and innovation across industries as co-chair for the Healthcare and Life Sciences Quantum Working Group co-founded by Cleveland Clinic and IBM and co-chair for the AI Alliance formed by IBM and Meta. She also serves advisory roles in data and technology for industry and federal agencies including the National Institutes of Health, Food and Drug Administration and the National Academy of Medicine. In January 2026, she was appointed to the Advisory Committee to the newly created Office of Science at the US Department of Energy.
Dr. Jehi, a long-time innovator, led the development of the first nomograms for individualized outcome prediction after epilepsy surgery. Her work was featured by Lancet Neurology in the Top 5 Innovations of 2015, and in the “Notables in Healthcare” Award by Crain’s Business in 2021. Her data-driven algorithms for clinical care decision-making are being used, studied and expanded worldwide. She is a sought-after speaker with >80 keynotes on technology and medicine globally, including the House of Lords in UK, and Karolinska Institute in Sweden.
Dr. Jehi’s research contributions include more than 200 peer-reviewed publications and 12 book chapters. She spearhead multiple multi-institutional National Institutes of Health- funded grants focused on data science. As co-director of Network Capacity for the Clinical and Translational Science Collaborative of Cleveland, Dr. Jehi facilitated multi-center clinical trials through streamlined recruitment efforts, using electronic health records. She is the principal investigator of Cleveland Clinic’s Biorepository, a role leveraging information technology, enterprise analytics and regulatory support to efficiently scale up and incorporate biobanking efforts within clinical workflow. She served as a vice-chair of Cleveland Clinic’s Institutional Review Board and currently chairs several key committees in the International League Against Epilepsy and the American Epilepsy Society.
Dr. Jehi received her medical degree from American University of Beirut. She completed her residency in neurology and fellowship in clinical neurophysiology at Cleveland Clinic, and holds a Master’s of Health Care Delivery Science from Dartmouth College.
IBM Fellow, Vice President of IBM Research Europe and Africa,
Director of the IBM Research Lab in Zurich, Switzerland
IBM
Dr. Alessandro Curioni is an IBM Fellow, Vice President of IBM Research Europe and Africa and Director of the IBM Research Lab in Zurich, Switzerland. He is responsible for IBM's global research strategies in Accelerated Discovery and Security. Currently, his research interests include accelerating the rate of scientific discovery leveraging AI, Quantum, and Hybrid Cloud. Dr. Curioni received his PhD in Theoretical Chemistry from Scuola Normale Superiore, Pisa, Italy. He is a member of the Swiss Academy of Technical Sciences.
Jianying Hu is an IBM Fellow, Director of HCLS Research, and Global Science Leader of AI for Healthcare at IBM. She is also Adjunct Professor of Medicine at Icahn School of Medicine at Mount Sinai. Dr. Hu joined IBM in 2003 after working at Bell Labs. She has over 30 years of experience conducting and leading research on machine learning, with recent focus on AI enabled acceleration of scientific discovery in health. Dr. Hu has served on many editorial and advisory boards, most recently on the National Academy of Medicine’s Committee on Establishing a Framework for Emerging Science, Technology and Innovation in Health and Medicine, and the External Advisory Board of the NIH AIM-AHEAD Program. Dr. Hu is a fellow of the American College of Medical Informatics, International Academy of Health Sciences Informatics, IEEE, and the International Association of Pattern Recognition.
Director of the Institute for Medical Engineering & Science
J. W. Kieckhefer Professor in the Department of Chemistry
Extramural Member of The Koch Institute for Integrative Cancer Research
MIT
Alex K. Shalek, PhD, is the Director of the Institute for Medical Engineering & Science (IMES), the J. W. Kieckhefer Professor in the Department of Chemistry, and an Extramural Member of The Koch Institute for Integrative Cancer Research at MIT. He is also an Institute Member of the Broad Institute, a Member of the Ragon Institute, an Assistant in Immunology at MGB, and an Instructor in Health Sciences & Technology at HMS. Dr. Shalek received his bachelor's degree summa cum laude from Columbia University and his Ph.D. from Harvard University in chemical physics under the guidance of Hongkun Park, and performed postdoctoral training under Hongkun Park and Aviv Regev (Broad/MIT). His lab’s research is directed towards the development and application of new approaches to elucidate cellular and molecular features that inform tissue-level function and dysfunction across the spectrum of human health and disease. Dr. Shalek and his work have received numerous honors including a NIH New Innovator Award, a Beckman Young Investigator Award, a Searle Scholar Award, a Pew-Stewart Scholar Award, the Avant-Garde (DP1 Pioneer) Award from the National Institute for Drug Abuse (NIDA), and an Alfred P. Sloan Research Fellowship in Chemistry, as well as the 2019-2020 Harold E. Edgerton Faculty Achievement Award at MIT and the 2020 HMS Young Mentor Award.
Founding and Current Chief Executive Officer
Structural Genomics Consortium
Temerty Nexus Chair of Health Technology and Innovation
University of Toronto
Aled Edwards is the founding and current CEO of the Structural Genomics Consortium (SGC), a charity and public-private partnership in early drug discovery formed in 2002, and is now spearheading the Target 2035 initiative, which aims to develop a chemical probe for every human protein. Aled is the Temerty Nexus Chair of Health Technology and Innovation at the University of Toronto.
Dr. Stacey Adam is a Vice President of Science Partnerships at the FNIH, leading many public-private partnerships (PPPs), such as RECOVER-Treating Long COVID; the Biomarkers Consortium (Cancer and Metabolic Disorders Steering Committees) and their projects; Accelerating Medicines Partnerships (AMPs)-Common Metabolic Diseases, Heart Failure, and Parkinson’s Disease, Partnership for Accelerating Cancer Therapies (PACT); and the Lung Master protocol (Lung-MAP) clinical trial. She also helps to lead multiple efforts to design new PPPs to address specific issues, such as the clinical testing of pediatric medical devices, systems biology of cancer, and the development of a validation and qualification network for new approach methodologies (NAMs).
Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting in the Federal Life Sciences and Healthcare Strategy practice, where she supported many federal and non-profit client projects. Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, where she was both an NIH- and American Cancer Society-supported fellow, and she earned her PhD in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.
James Kozloski joined IBM Research in May 2001 where he's worked on AI and Biomedicine at the T.J. Watson Research Center in Yorktown Heights, NY. He was named an IBM Principal Research Scientist in 2022 and leads initiatives in Biomedical AI and Modeling, working with external collaborators across multiple fields, all of which are benefiting from improvements to models of cellular function driven by AI, agentic, and algorithmic innovation. As a manager and strategist, James oversees the use of AI to solve problems in stochastic complex systems for improving predictive biophysical models of disease and drug mechanism. His team focuses on applying algorithm-informed foundation models and generative AI to model-based therapeutic design and discovery. In 2017 he was inducted into IBM's Academy of Technology. Beyond publishing scientific discoveries, James has authored over 300 patents issued for IBM in areas such as neurotechnology, biomedical AI, and computer science. In 2010, he was named an IBM Master Inventor. He joined IBM after completing a postdoctoral fellowship at Columbia University, and he received his PhD. in Neuroscience and Biomedical Graduate Studies from the University of Pennsylvania in 1999. In 1992, he received a B.A. from the University of Virginia, having double majored in English and Biology as a Jefferson Scholar. Prior to graduate school, he worked in the Laboratory of Human Genetics in New York City, studying the rare genetic disorder Bloom Syndrome, and contributing to the discovery of the gene responsible for it.
Chief Academic Officer for the Heart and Vascular Institute
Lewis and Patricia Dickey Chair and Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Steven E. Nissen MD MACC is Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, the Lewis and Patricia Dickey Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. From 2006 to 2019, he served as Chair of the Department of Cardiovascular Medicine. In 2006-2007 he served as President of the American College of Cardiology. Dr. Nissen has published more than 750 journal articles. In 2007, Time Magazine selected Dr. Nissen as one of the world’s 100 most influential people. Thompson-Reuters lists him as one of the world’s most highly cited physician-scientists.
Curtis Priem graduated from Rensselaer Polytechnic Institute in 1982 with a major in Computer Systems Engineering and minors in Computer Science and Music. He architected and designed the first graphics accelerator for the Personal Computer: the IBM Professional Graphics Controller in 1983 and created the first CGI ray trace image on a PC. In 1984 Priem joined GenRad Inc. working in their board and chip testing simulator group designing the HiChip product line. He went on to be the architect of the Sun Microsystem’s GX which was the standard graphics accelerator across all Sun's workstations. He co-founded Nvidia Corporation in 1993 and was the architect of Nvidia’s NV Architecture which the Integrated Media Interface (IMI), the Graphics Processor Unit (GPU), the Unified Driver Architecture (UDA), and the Compute Unified Device Architecture (CUDA) products were built upon. He is an inventor on almost 200 U.S. and international patents. Curtis is currently the Vice Chair of RPI’s Board of Trustees and his foundation has invested over $100M to fund the RPI's pedagogy, research, and the installation of the IBM Quantum System One, the first and only quantum computer on a university campus.
Heather Higgins is a Partner in IBM Quantum. In this role, Heather leads a team of global quantum industry and technical experts working with enterprise clients who are evaluating and adopting quantum technology for future impact. She has been with IBM for over 25 years and has served in global roles across multiple business units throughout the organization.
Heather has deep expertise at the intersection of enterprise strategy and emerging technology combined with proven experience helping
organizations harness technology to unlock new business value. She is well known as a results driven business leader who helps innovative clients drive their transformation agenda. Heather has a B.S. in International Business Management and Management Information Systems from Northeastern University.
Hsin-Yuan Huang (Robert) is an Assistant Professor of Theoretical Physics and a William H. Hurt Scholar at Caltech. He completed his Ph.D. at Caltech under John Preskill and Thomas Vidick. His research leverages learning theory to advance quantum computation, physics, and information science, with contributions including classical shadow tomography, machine learning algorithms for quantum many-body problems, and quantum advantages in learning from experiments. His work has appeared in premier venues including Nature, Science, FOCS, and STOC, and has delivered over 180 invited talks. His doctoral thesis "Learning in the Quantum Universe" earned the Milton and Francis Clauser Doctoral Prize for the most original research among all 2024 Caltech graduates, and he holds additional honors including the Google Ph.D. Fellowship, Boeing Quantum Creator Prize, and the William H. Hurt Scholar endowed professorship.
Associate Staff, Computational Life Sciences, Cleveland Clinic
Assistant Professor, Molecular Medicine, Cleveland Clinic Lerner College of Medicine
Daniel Blankenberg, PhD, is Associate Staff in the Department of Computational Life Sciences at Cleveland Clinic and an Assistant Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. His laboratory develops FAIR (Findable, Accessible, Interoperable, Reusable) computational approaches that help researchers access, analyze, and visualize large-scale biological data, with an emphasis on methods that are reproducible in practice and usable in real scientific workflows.
Dr. Blankenberg received his PhD in Biochemistry, Microbiology and Molecular Biology from Pennsylvania State University and a BS in Biochemistry & Molecular Biology and Computer Science from Gettysburg College. He has worked in computational biology for more than two decades and is a founding member and current co-lead of the Galaxy Project.
His research spans functional and comparative genomics, protein sequence-function analysis, and genome variation and benchmarking, focused on enabling trustworthy biological and clinical conclusions from complex data. His work also includes data-driven methods for high-dimensional biology and emerging computing paradigms, including quantum computing applications for biomedical discovery. He serves as Cleveland Clinic’s lead for Quantum Computing within the Cleveland Clinic-IBM Discovery Accelerator.
President and University Professor
Mohamed Bin Zayed University of Artificial Intelligence
Carnegie Mellon University
Professor Eric Xing is the President of the Mohamed bin Zayed University of Artificial Intelligence, and a Professor of Computer Science at Carnegie Mellon University. His main research interests are the development of machine learning and statistical methodology, and large-scale distributed computational system and architectures, for solving problems involving automated learning, reasoning, and decision-making in in artificial, biological, and social systems. In recent years, he has been focusing on building large language models, world models, agent models, and foundation models for biology.
Prof. Xing has served on the editorial boards of several leading journals including JASA, AOAS, JMLR; was a recipient of several awards including NSF Career, Sloan, Carnegie Science Award, and best papers in conferences such as ACL, ISMB, NeurIPS, and OSDI; and is a fellow of several societies including AAAI, ACM, ASA, IEEE, and IMS.
Percy Carter, PhD, is a biopharmaceutical executive with more than 25 years of global leadership experience spanning drug discovery, translational science, and R&D strategy. He joined Pfizer as Head of Preclinical and Translational Sciences at Pfizer in late 2025. Prior to this role, Dr. Carter was Chief Scientific Officer at Blueprint Medicines, where he championed a highly coordinated, science‑led R&D model prior to its acquisition by Sanofi in 2025 and previously served as Chief Scientific Officer at FibroGen. Earlier in his career, he spent nearly two decades at Bristol‑Myers Squibb, ultimately serving as Senior Vice President and Head of Discovery, and also held senior leadership roles at Johnson & Johnson. Dr. Carter authored or co-authored over 85 peer‑reviewed publications and is an inventor on 28 issued U.S. patents. He holds an A.B. in Chemistry from Dartmouth College, a Ph.D. in Organic Chemistry from Harvard University, and an M.B.A. from the Massachusetts Institute of Technology, and has served on the boards of multiple biotechnology and nonprofit organizations.
Eric D. Isaacs is President and CEO of Research Corporation for Science Advancement (RCSA) since July 1, 2025, continuing the foundation’s long-standing mission to support pioneering research in the physical sciences and develop future scientific leaders. He also serves as president-elect of the American Association for the Advancement of Science and will assume that role in 2027. Prior to RCSA, Dr. Isaacs was president of the Carnegie Institution for Science from 2018 to 2024, where he led a strategic reorganization to strengthen interdisciplinary research across astronomy, biology, and planetary sciences. Earlier, as Provost and Executive Vice President for Research at the University of Chicago, he oversaw more than $1.5 billion in sponsored research and major affiliated laboratories, including Argonne National Laboratory and Fermilab.
Dr. Isaacs earned his B.A. in physics from Beloit College and his Ph.D. from the Massachusetts Institute of Technology, followed by postdoctoral work and a 15-year research career at Bell Laboratories. An experimental physicist, his work has spanned condensed matter physics, and energy technologies, with a focus on nanoscale phenomena and advanced X-ray scattering techniques. He is a Fellow of the National Academy of Inventors and the American Physical Society.
Dr. Sarah Sheldon is a principal research scientist and the head of applied quantum science at IBM Quantum. She received her Ph.D. in nuclear science and engineering from MIT in 2013, where she studied quantum control techniques. She then joined IBM and has done research on improving gate calibrations in superconducting qubits, developing techniques for characterizing quantum devices, and extending the capabilities of current quantum systems. Her team now focuses on developing novel algorithms and applications for quantum computing that will be accessible in the near term.
Division Director, Quantum HPC Hybrid Computing Platform
Riken Center for Computational Science
Professor, Juntendo University
Professor Emeritus, University of Tsukuba
Dr. Sato is the division director of Quantum HPC Hybrid Computing Platform Division in RIKEN Center for Computational Science (R-CCS) since 2023. He received his MS and PhD in information science from the University of Tokyo in 1984 and 1990. From 2014 to 2020, he was working as a team leader of the architecture development team in FLAGSHIP 2020 project to develop the Japanese flagship supercomputer, Fugaku. Dr. Sato was appointed to deputy Director of R-CCS from 2018 to 2023. Since 2023, he has served as a Professor at Juntendo University and Professor Emeritus of University of Tsukuba.
Associate Director of Policy & International Engagement
Engineering Biology Research Consortium (EBRC)
Dr. Dunlap is the Associate Director of Policy & International Engagement at EBRC, where he works to advance engagement with U.S. policymakers by highlighting the economic and societal value of biotechnology, and shape public policies that support its community. Before this, he was Head of Science and Innovation at the British Consulate-General in New York, fostering UK-US science and tech collaborations. Dr. Dunlap previously worked as a Graduate Fellow at the Wilson Center, focusing on risks from converging technologies, and as a Science Diplomacy Fellow with the Netherlands Innovation Network, exploring deep tech innovation ecosystems. In addition to his current role, Dr. Dunlap is a Fellow for Ending Bioweapons with the Council on Strategic Risks, and also participates in the World Economic Forum working group on the Bioeconomy. He holds a Ph.D. in Biological and Biomedical Sciences from Harvard University and undergraduate degrees in Biology and Political Science from Case Western Reserve University.
Heidi Workman serves as the State Representative for Ohio’s 72nd House District, representing most of Portage County with a focus on practical solutions, property tax relief, and support for small businesses. A small business owner and registered nurse with two decades of healthcare experience, she brings firsthand knowledge of the challenges facing entrepreneurs and patients alike. Elected in 2024, she serves as Vice Chair of the Technology and Innovation Committee and was appointed to serve on the National Conference of State Legislatures (NCSL) Task Force on AI, Cybersecurity, and Privacy, promoting policies that drive economic growth and technological advancement in Ohio. Workman also holds roles on the Government Oversight, Natural Resources, and Workforce & Higher Education committees, focusing on accountability, sustainable resource management, and education-to-employment opportunities that meet community urgent workforce needs. Workman is a strong advocate for reducing regulations, easing burdens on small businesses, and helping families plan for affordable higher education. A proud Ohioan, she holds degrees from Bowling Green State University and Kent State University and lives in Portage County with her husband and four children.
Lord Bethell is an entrepreneur, former health minister and champion for public health. He has a twenty-year track record working across government, media and industry, working at The Sunday Times, the US Senate, and the EU Commission. He has built and sold communications companies and helped make the Ministry of Sound a global success story. As a minister at the Department for Health and Social Care, he helped lead the UK national response to the Covid epidemic. He is currently a member of the House of Lords, chairman of Business for Health, a Fellow at King’s College London and a senior counsel to several health companies.
Geetha Senthil is the Deputy Director for the Office of Special Initiatives at National Center for Advancing Translational Sciences (NCATS) within National Institutes of Health (NIH).
She is keen on exploring cross-cutting opportunities in developing innovative technologies applicable to biomedical fields through leveraging resources, expertise, and partnerships across NIH ICs, federal agencies, national and international stakeholders.
Dr. Senthil Coordinates NIH quantum Efforts. She launched two prize challenges under the Quantum Biomedical Innovations and Technologies (Qu-BIT) Program. These include:
1) Quantum Sensing Technology Challenge that invites multi-disciplinary collaborative teams to develop new biomedical use cases of existing quantum-enabled sensing technologies that will enable early detection and accurate diagnosis, improved patient care and health monitoring, and develop point of care wearables and portable devices; and
2) Quantum Computing Challenge is designed to develop quantum algorithms for in silico drug discovery, modeling and simulations, as well as imaging and multi-omics analyses. Dr. Senthil is keen on developing innovative technologies applicable to biomedical fields through leveraging resources, and partnerships across national and international stakeholders.
Hal Paz is an operating partner at Khosla Ventures and has served as a senior executive and board member across healthcare providers, payers, and medical technology companies. He previously served as Executive Vice President and Chief Medical Officer of CVS Health/Aetna; Chancellor for Health Affairs and CEO of The Ohio State University Wexner Medical Center; and CEO of Penn State Health and
Stony Brook University Medicine.
Dr. Paz currently serves on the boards of Envision Healthcare and Research!America and previously served on the boards of Select Medical, USPI, Vyteris, the AAMC and seven health systems. He advises Curai Health and has previously advised Johnson & Johnson and USPI. He has also served on committees of the National Academy of Medicine and the National Academies.
A former medical school dean, at Robert Wood Johnson and Penn State, and physician–scientist, Dr. Paz has conducted research in sepsis, ARDS, and medical devices and has authored more than 100 publications. He earned his BA and MD from the University of Rochester and an MS in Life Science Engineering from Tufts University, completed residency training at Northwestern University, and completed fellowships at Johns Hopkins University in pulmonary and critical care medicine and environmental health sciences.
Ran Balicer, MD, PhD, MPH, is Chief Innovation Officer and Deputy Director-General of the Clalit Group - Israel's largest Healthcare Organization caring for over half of the country population. He also serves as Founding Director of the Clalit Research Institute - the WHO Collaborating Center on Non-Communicable Diseases Research, Prevention and Control. In these roles, he has been responsible for strategic planning, development and at-scale implementation of novel AI intervention, and for the decades-long digital transformation of half of Israel’s healthcare system.
Dr. Balicer is a Public Health Professor, and as Healthcare Chair of the AI Institute at Ben-Gurion University, Israel. He also heads Israel’s unique Public Health/Data Sciences Physician Residency Program. He is the founding Co-Chair of the Berkowitz Living Laboratory at Harvard Medical School & CRI and additionally serves as an Honorary Professor at Charité Universitätsmedizin, Berlin. In these capacities, Dr. Balicer mentors young scholars in both Israel and Germany and has authored over 300 scientific publications and books.
In 2020-2022, Dr. Balicer served as Chairman of Israel's National Experts Team on COVID-19 Response, advising the Israeli Government and Prime Minister, as well as decision makers worldwide. He has led globally recognized groundbreaking real-world studies on COVID-19 risk stratification, mitigation strategies, and most notably – the first population-wide studies on COVID-19 vaccine effectiveness and safety.
Dr. Balicer recently served key roles on AI governance globally, including on the United Nations High-Level Advisory Body on AI, and on the 3IA/AI cluster International Advisory Board to the French Government. He currently holds multiple national and global leadership roles, including as a member of the Global Board of HIMSS, as a member of the WHO Europe Technical Advisory Group on Innovation, and as the Chair of the Israeli Society for Quality in Healthcare.
Jean-Claude leads the development of Tom, an AI-powered care team member that delivers “Primary care as a Service” to improve care for patients, clinicians and health systems. He is passionate about seamlessly integrating technology into clinical workflows.
Jean-Claude previously served as CTO of Wolters Kluwer Health, overseeing AI Innovation and clinical decision support and as general Manager & CTO of Cardinal health’s RFID business, where he advanced medical device tracking. He was also the CTO of WaveMark, a healthcare startup acquired by Cardinal Health.
He holds an MS in Engineering and Management from MIT Sloan, an MS from MIT and BS in Engineering from UMass. Jean-Claude holds multiple patents and serves on several boards.
Anagha Vyas is the VP of Artificial Intelligence at Lumeris, where she leads the strategy and development of autonomous, multi-agent AI systems for healthcare. Spearheading "Tom," a primary care AI operating system, she translates complex data into proactive actions. Passionate about building Trust in AI, her expertise bridges rigorous governance, transparent models, and scalable technology to safely reduce physician burnout and act as a reliable force multiplier for care teams.
Tim Wahlberg is Interim President of CAS, helping innovators answer the world’s most complex scientific questions through science‑smart, AI‑enhanced solutions and services. Wahlberg joined CAS in 2018 as Chief Product Officer, bringing more than 25 years of experience conceiving, building, and scaling innovative information, software, and services solutions. Over the course of his career, he’s had the opportunity to work with and learn from outstanding teams at organizations including ProQuest, Thomson Reuters, The Hearst Corporation, and Oliver Wyman, developing a deep understanding of how trusted information fuels better decisions.
Wahlberg holds an MBA with distinction from Northwestern University’s J.L. Kellogg Graduate School of Management and a BA, summa cum laude, from the University of Minnesota. Outside of work, he enjoys rehabilitating old homes, city getaways, and playing ice hockey.
Manuel Guzman is the President of CAS, a division of the American Chemical Society, where he leads strategic initiatives that harness content and knowledge management to accelerate scientific discovery. Under his leadership, CAS collaborates with global research and development organizations and domain experts to integrate curated scientific content with advanced technologies, including AI, driving innovation that improves lives around the world.
Since joining CAS in 2013, Manuel has brought a global perspective and a deep commitment to empowering others. His career spans executive roles across the information and education sectors, including EVP of Learning, Research Solutions & International at Cengage Learning, President and CFO of Thomson Learning’s Career & Professional Group, and Co-founder and CEO of Monument Information Resource/MIR Management Corporation. He holds a B.S. in Accounting and an MBA in Finance from Seton Hall University.
Chief Clinical Business Development Officer and holder of the Violette Magyar Chair of Plastic and Reconstructive Craniofacial Surgery
Cleveland Clinic
Dr. Papay recently served as the President of the American Society of Maxillofacial Surgeons and is a traveling visiting professor of the American Association of Plastic Surgeons including the AAPS Research Achievement Award for Innovation.
He has published over 260 publications including co-authoring four books, "Reconstructive Allotransplantation”, “Strategies for Artificial Intelligence in Healthcare, co-edited “Voices of Innovation-Fulfilling the Promise of AI in Healthcare” and "Virtual Surgical Planning in Plastic Surgery". Dr. Papay was the lead surgeon on America's first face transplant with Dr. Maria Siemionow and has led two additional face transplantations at the Cleveland Clinic. Dr. Papay has dozens of honors including an honorary Doctor of Science degree from Ohio University, the Sones Centennial Innovation award, an honorary Doctor of Science degree from Northeast Ohio Medical University, elected Fellow in the National Academy of Inventors, the WebMD Hero award in Science, The Cleveland Clinic's George Crile Founders travelling fellowship award, the Northeast Ohio Medical University alumni award, and the honorary ASMS/ASPS Converse lecture among others.
Dr. Papay attended Case Western Reserve University’s biomedical engineering program and is currently finishing a DBA at Case. After finishing medical school at Northeast Ohio University, he became double boarded in Otolaryngology, Head and Neck Surgery followed by Plastic and Reconstructive Surgery at the Cleveland Clinic, a travelling fellowship in maxillofacial surgery in Switzerland then a craniofacial fellowship at the University of Utah. Dr. Papay holds dozens of patents and has co-founded three Cleveland Clinic spin-off companies, with interest in neuromodulation for obstructive sleep apnea, cluster headaches, and other drug delivery medical devices and implants. Dr. Papay' s current interest involves the creation of artificial intelligence programs for efficient healthcare operations, AI + CBT control of chronic disease conditions, and non-fiducial surgical navigation with wearable microscopes, augmented reality and fluorescence guided surgery. He is a co-founder of the "BrainX.AI community", a world-wide community of physicians and computer scientists contributing to open source sharing of data, and the creation of a free AI healthcare learning platform.
Professor, Computer Science
Co-Chair, Center of Excellence for Smart Health
Chair, Bioinformatics Platform
King Abdullah University of Science and Technology-Saudi Arabia
Susan K. Gregurick, Ph.D., was appointed Associate Director for Data Science and Director of the Office of Data Science Strategy (ODSS) at the National Institutes of Health (NIH) on September 16, 2019. Under her leadership, ODSS leads the implementation of the NIH Strategic Plan for Data Science through scientific, technical collaboration with the institutes, centers, and offices that comprise NIH. Dr. Gregurick received the 2020 Leadership in Biological Sciences Award from the Washington Academy of Sciences, which recognizes work of merit and distinction of scientists and leaders in the greater Washington area.
Dr Magistretti received his MD in 1979 from the University of Geneva and his PhD in Biology in 1982 from UCSD. He is the Professor Emeritus at the Brain Mind Institute at EPFL and in the Departments pf Psychiatry at the University of Lausanne and the University of Geneva. Dr Magistretti is also a Distinguished Professor in the Division of Biological and Environmental Sciences and Engineering at KAUST, where he served as Dean from 2012 to 2020 and Vice President of Research since 2022.
Dr. Magistretti and his lab have discovered some of the cellular and molecular mechanisms that underlie the coupling between neuronal activity and energy consumption by revealing the key role of glial cells, particularly astrocytes, in this physiological process. These findings are especially relevant for understanding the origin of the signals detected by functional brain imaging and are revealing a role for astrocytes in neuronal plasticity and neuroprotection.
Dr. Krishna is an Associate Staff member of Biomedical Engineering at Cleveland Clinic Research. His interdisciplinary laboratory develops functional nanotechnologies for disease prevention and therapy, with a focus on proactive healthcare, precision photoprotection, antimicrobial technologies, and photodynamic treatment strategies. His research emphasizes structure–property relationships and light-matter interactions that govern therapeutic performance. Dr. Krishna is a Co-PI on a Wellcome Leap Quantum for Bio–funded initiative exploring how advanced quantum chemical simulations and emerging quantum computing algorithms can improve prediction of photochemical processes relevant to precision therapy. He holds 25 patents and 6 PCT applications and is engaged in translating laboratory discoveries toward clinical impact.
Associate Director for Data Science and Director of the Office of Data Science Strategy
National Institutes of Health
Susan K. Gregurick, Ph.D., was appointed Associate Director for Data Science and Director of the Office of Data Science Strategy (ODSS) at the National Institutes of Health (NIH) on September 16, 2019. Under her leadership, ODSS leads the implementation of the NIH Strategic Plan for Data Science through scientific, technical collaboration with the institutes, centers, and offices that comprise NIH. Dr. Gregurick received the 2020 Leadership in Biological Sciences Award from the Washington Academy of Sciences, which recognizes work of merit and distinction of scientists and leaders in the greater Washington area.
Dr. Hamilton is an early career research staff member in the Quantum Computational Science Group. Since joining Oak Ridge National Laboratory in 2016 she has worked on several projects focusing on the development of algorithms, methods and applications for near-term, next-generation processors (e.g. quantum computers and neuromorphic computers).
Dr. Hamilton is currently focused on hybrid workflows that use classical and next-generation platforms. This work allows her to leverage my diverse research background in quantum computing, discrete mathematics, and correlated dynamics. What Dr. Hamilton finds fascinating about her research is discovering how different components of hybrid workflows interact, and how this can be used to build scalable applications that are noise robust. In addition to understanding the capabilities of near-term hardware, Dr. Hamilton’s work has also resulted in demonstrations of real-world applications such as epidemic modeling.
Welcome and Panel Introduction
Featuring:
Tom Mihaljevic, MD | CEO & President, Cleveland Clinic
Brian Donley, MD | CEO, Cleveland Clinic London
Jamanda Haddock, MA, MRCP, FRCR | Associate Chief of Staff and Chair of Hospital Services, Cleveland Clinic London
Moderated by: Angela Rossi, Chief Human Resources Officer
Panel Discussion and Audience Q&A
Chair of the Board Remarks | Beth Mooney
Ribbon Cutting Ceremony
For additional information or questions, please contact Cleveland Clinic's Computational Life Sciences at ComputationalLifeSci@ccf.org.